Purpose

The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.

Condition

Eligibility

Eligible Ages
Between 18 Years and 85 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • English speaking - able to sign informed consent - able to arrange transportation to and from study site - without acute stroke, concussion or traumatic brain injury - without acute medical issues at the time of participation - At least 12 weeks post Kidney transplant surgery

Exclusion Criteria

  • are claustrophobic or have other contra-indication for magnetic resonance imaging (MRI) - have hearing or visual impairment - are unable to read, write, speak or understand English - have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics - taking Envarsus at the time of recruitment

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Conversion Group Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
  • Drug: Tacrolimus
    The patient's physician will prescribe drug according to standard practice.
    Other names:
    • Prograf
  • Drug: Everolimus
    The patient's physician will prescribe drug according to standard practice.
Control Group Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
  • Drug: Tacrolimus
    The patient's physician will prescribe drug according to standard practice.
    Other names:
    • Prograf

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160

More Details

Status
Unknown status
Sponsor
University of Kansas Medical Center

Study Contact

Andrew Jurgensen
913-574-0895
ajurgensen@kumc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.